Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]
J Clin MedMansour GK +5 more
europepmc +1 more source
Erratum: Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
Frontiers in Physiology, 2022 Frontiers Production Office
doaj +1 more source
Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]
Curr Cardiol RepPanichella G +8 more
europepmc +1 more source
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM [PDF]
Olivotto, Iacopo
core +1 more source
ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy). [PDF]
Eur Heart J Cardiovasc PharmacotherMonda E, Limongelli G.
europepmc +1 more source
Mavacamten in hypertrophic obstructive cardiomyopathy with hepato-renal comorbidities: A case report. [PDF]
Medicine (Baltimore)Ma L, Li F, Dong S, Li R.
europepmc +1 more source
Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening [PDF]
, 2023 Attili, Seetharamaiah +5 more
core +3 more sources
Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. [PDF]
J Clin MedReza N +12 more
europepmc +1 more source
Complete left bundle branch block resolution during treatment with Mavacamten: a case report of a first-in-class scenario. [PDF]
Eur Heart J Case RepMarchionni G +4 more
europepmc +1 more source
Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants [PDF]
Olivotto, Iacopo
core +1 more source